HALO
Price
$62.43
Change
+$0.33 (+0.53%)
Updated
Aug 8, 12:05 PM (EDT)
Capitalization
7.27B
94 days until earnings call
IDYA
Price
$22.44
Change
+$0.03 (+0.13%)
Updated
Aug 8, 10:39 AM (EDT)
Capitalization
1.96B
95 days until earnings call
Interact to see
Advertisement

HALO vs IDYA

Header iconHALO vs IDYA Comparison
Open Charts HALO vs IDYABanner chart's image
Halozyme Therapeutics
Price$62.43
Change+$0.33 (+0.53%)
Volume$182
Capitalization7.27B
IDEAYA Biosciences
Price$22.44
Change+$0.03 (+0.13%)
Volume$100
Capitalization1.96B
HALO vs IDYA Comparison Chart in %
Loading...
HALO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HALO vs. IDYA commentary
Aug 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HALO is a Buy and IDYA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 08, 2025
Stock price -- (HALO: $62.12 vs. IDYA: $22.41)
Brand notoriety: HALO and IDYA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: HALO: 98% vs. IDYA: 63%
Market capitalization -- HALO: $7.27B vs. IDYA: $1.96B
HALO [@Biotechnology] is valued at $7.27B. IDYA’s [@Biotechnology] market capitalization is $1.96B. The market cap for tickers in the [@Biotechnology] industry ranges from $199.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HALO’s FA Score shows that 1 FA rating(s) are green whileIDYA’s FA Score has 0 green FA rating(s).

  • HALO’s FA Score: 1 green, 4 red.
  • IDYA’s FA Score: 0 green, 5 red.
According to our system of comparison, HALO is a better buy in the long-term than IDYA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HALO’s TA Score shows that 6 TA indicator(s) are bullish while IDYA’s TA Score has 3 bullish TA indicator(s).

  • HALO’s TA Score: 6 bullish, 4 bearish.
  • IDYA’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, HALO is a better buy in the short-term than IDYA.

Price Growth

HALO (@Biotechnology) experienced а +3.59% price change this week, while IDYA (@Biotechnology) price change was -7.97% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.01%. For the same industry, the average monthly price growth was +6.37%, and the average quarterly price growth was +12.35%.

Reported Earning Dates

HALO is expected to report earnings on Nov 10, 2025.

IDYA is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+0.01% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HALO($7.27B) has a higher market cap than IDYA($1.96B). HALO YTD gains are higher at: 29.931 vs. IDYA (-12.802). HALO has higher annual earnings (EBITDA): 705M vs. IDYA (-356.46M). HALO has more cash in the bank: 748M vs. IDYA (693M). IDYA has less debt than HALO: IDYA (26M) vs HALO (1.51B). HALO has higher revenues than IDYA: HALO (1.08B) vs IDYA (7M).
HALOIDYAHALO / IDYA
Capitalization7.27B1.96B370%
EBITDA705M-356.46M-198%
Gain YTD29.931-12.802-234%
P/E Ratio14.22N/A-
Revenue1.08B7M15,486%
Total Cash748M693M108%
Total Debt1.51B26M5,796%
FUNDAMENTALS RATINGS
HALO vs IDYA: Fundamental Ratings
HALO
IDYA
OUTLOOK RATING
1..100
1871
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
62
Fair valued
PROFIT vs RISK RATING
1..100
3678
SMR RATING
1..100
1296
PRICE GROWTH RATING
1..100
4848
P/E GROWTH RATING
1..100
87100
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IDYA's Valuation (62) in the null industry is in the same range as HALO (79) in the Biotechnology industry. This means that IDYA’s stock grew similarly to HALO’s over the last 12 months.

HALO's Profit vs Risk Rating (36) in the Biotechnology industry is somewhat better than the same rating for IDYA (78) in the null industry. This means that HALO’s stock grew somewhat faster than IDYA’s over the last 12 months.

HALO's SMR Rating (12) in the Biotechnology industry is significantly better than the same rating for IDYA (96) in the null industry. This means that HALO’s stock grew significantly faster than IDYA’s over the last 12 months.

HALO's Price Growth Rating (48) in the Biotechnology industry is in the same range as IDYA (48) in the null industry. This means that HALO’s stock grew similarly to IDYA’s over the last 12 months.

HALO's P/E Growth Rating (87) in the Biotechnology industry is in the same range as IDYA (100) in the null industry. This means that HALO’s stock grew similarly to IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HALOIDYA
RSI
ODDS (%)
Bearish Trend 1 day ago
59%
Bearish Trend 1 day ago
64%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
60%
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 5 days ago
67%
Bearish Trend 1 day ago
81%
MACD
ODDS (%)
N/A
Bearish Trend 1 day ago
76%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 16 days ago
77%
Declines
ODDS (%)
Bearish Trend 8 days ago
68%
Bearish Trend 1 day ago
77%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
50%
Bearish Trend 1 day ago
71%
Aroon
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
HALO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FEUPX61.540.75
+1.23%
American Funds EUPAC F3
HIOCX18.07N/A
N/A
Hartford International Opportunities C
HMVYX17.82N/A
N/A
Hartford MidCap Value Y
NSMVX40.64N/A
N/A
North Star Micro Cap I
VVJFX74.64N/A
N/A
Voya Multi-Manager Intl Sm Cp R6

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with IMNM. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
-5.16%
IMNM - IDYA
61%
Loosely correlated
-5.64%
CGON - IDYA
60%
Loosely correlated
-3.80%
SYRE - IDYA
60%
Loosely correlated
-4.51%
NRIX - IDYA
59%
Loosely correlated
-3.63%
XENE - IDYA
58%
Loosely correlated
-1.84%
More